Logo-ijhpm
Int J Health Policy Manag. 2022;11(8): 1489-1495. doi: 10.34172/ijhpm.2021.47
PMID: 34273922        PMCID: PMC9808358

Original Article

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis

Cong Huang 1 ORCID, Carolina Oi Lam Ung 2, Haishaerjiang Wushouer 1,3, Lin Bai 1, Xinyi Li 1, Xiaodong Guan 1 * ORCID, Luwen Shi 1 ORCID

Cited by CrossRef:

1- You M, Zeng X, Zhang J, Huang Y, Zhang Y, Cai Z, Hu Y. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer. Front Immunol. 2023;14 [Crossref]
2- Meng W, Yang S, Wang Z, Xie J, Jiang R. Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective. BMC Public Health. 2024;24(1) [Crossref]
3- Liu Y, Yi H, Fang K, Bao Y, Li X. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis. Front Public Health. 2022;10 [Crossref]
4- Sun Y, Zhu Z, Zhang J, Han P, Qi Y, Wang X, Yang L. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis. IJERPH. 2022;19(8):4578 [Crossref]
5- Gao X, Yu M, Sun Y, Zhang T, Li X, Zhang L, Wang C. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study. RMHP. 2024;Volume 17:2201 [Crossref]
6- Peng N, Du C, Gong Y, Long X, Wang C, Liu P. Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016–2024. BMJ Open. 2024;14(12):e087190 [Crossref]
7- Liu S, Dou L, Wang K, Shi Z, Wang R, Zhu X, Song Z, Li S. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12 [Crossref]
8- Cai L, Tao T, Li H, Zhang Z, Zhang L, Li X. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study. J Glob Health. 2022;12 [Crossref]
9- Yang Y, Zhang Y, Wagner A, Li H, Shi L, Guan X. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data. J Glob Health. 2023;13 [Crossref]
10- Sun Y, Qiang Y, Duan Y, Song Y. Impact of the National Drug Price Negotiation policy on the price, usage, and affordability of anticancer medicines in Shandong Province, China. Front Public Health. 2025;12 [Crossref]